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Abstract
Background: It has been discussed if the adverse health effect associated with the ingestion of trans fatty acids
correlates with the food source, as the composition of the isomers varies in different foods. We have investigated
the hepatocellular responses to the predominant trans fatty acid isomers in industrially produced partially
hydrogenated vegetable oils (elaidic acid) and products of ruminant origin (trans-vaccenic acid).
Results: The responses of HepG2-SF cells exposed to 100 μM fatty acids during 7 days were examined. Elaidic acid
decreased the cellular proliferation rate while trans-vaccenic acid had no effect. Analysis of cellular triacylglycerol
fractions showed, that both trans fatty acids were metabolized by HepG2-SF cells, although elaidic acid, to a higher
degree than trans-vaccenic, accumulated in the triacylglycerol fraction. Proteome analysis revealed that the overlap
of differentially regulated proteins only contained four proteins, suggesting that the two trans fatty acid isomers
affect the cells in different ways. The data are available via ProteomeXchange with identifier PXD000760.
Conclusions: Our investigations revealed that the hepatocellular response to the two most abundant dietary
positional C18:1 trans fatty acid isomers differ substantially. In addition, the results suggest that trans-vaccenic acid
does not affect cholesterol metabolism adversely compared to elaidic acid.
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Background
Trans fatty acids (TFA) in the human diet originate from
industrial partial hydrogenation of vegetable oils (iTFA)
and the naturally occurring TFA in milk and body fat of
ruminants (rTFA). The intake of iTFA can reach 9 % of
the total energy intake [1] whereas the intake of rTFA
rarely exceeds 0.5 % [2]. Dietary iTFA causes increased ra-
tios in plasma of total cholesterol and LDL-cholesterol to
HDL-cholesterol and of apoB to apoA1, therefore, increas-
ing the risk of cardiovascular disease (CVD) (reviewed in
[3]). The impact of rTFA on human health has also been
investigated, but the results have been inconclusive
(reviewed in [4]). Most studies do not show a relationship
between rTFA and CVD [5–7] although a few have indi-
cated an inverse association [8, 9]. In contrast to this
potential positive effect of rTFA in relation to CVD, a high
concentration of rTFA in serum and erythrocytes results
in an increased risk of breast cancer [10, 11].
The main iTFA isomer is the transΔ9-C18:1 named elai-
dic acid (EA), whereas the main isomer of rTFA is the
transΔ11-C18:1 named trans-vaccenic acid (transVA)
(40–60 % of rTFA [12]). The transVA originates from in-
complete biohydrogenation of polyunsaturated fatty acids
by microorganisms in the rumen of cows, goats and sheep
[13]. Besides from being the major rTFA, transVA is also a
constituent of iTFA contributing up to 5 % of the fat in
margarine and shortening. Additionally, EA is present in
rTFA, where it may constitute up to 10 % of the total
rTFA [12]. Consequently, both EA and transVA intake
may originate from several sources, complicating the
evaluation of the impact of the individual isomer on
human health. It is possible to enrich ruminant products
for transVA through feeding strategies, by increasing time
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on pasture and decreasing silage in cattle feed, but the ef-
fect on EA content has not been evaluated [14]. TFA iso-
mer distribution and content in iTFA varies depending on
starting oil, degree of hydrogenation, temperature and
catalyst [15, 16]. Knowledge about responses to individual
TFA isomers such as EA and transVA can contribute in
developing guidelines for the process of partial hydrogen-
ation of vegetable oils and food formulations by the indus-
try, but also in the context of feeding strategies for milk
and meat production.
Despite indications that differential responses to pos-
itional isomers exist [17, 18], to our knowledge the TFA
isomer specific effects in human have not been directly in-
vestigated through dietary intervention studies. Human
clinical studies comparing health impact of diets enriched
in dairy products with diets rich in hydrogenated vege-
table oils exist [19–21]. However, the effect caused by the
particular TFAs was difficult to ascertain because both
diets contained TFA mixtures with isomers in different
amount. In other studies, TFA replaced saturated fatty
acids or polyunsaturated fatty acids to keep calorie-intake
constant between experimental diets [22, 23]. The result
of these studies is likely a mixed effect of excluding some
fatty acids and including others, and it is difficult to deter-
mine the effects of particular dietary TFA isomers [4].
Only few studies have been conducted on cultures of
human cells to assess isomer specific responses in regards
to CVD risk. The studies have focused on inflammatory
markers in endothelial cells [24] and monocytes [25], and
the results indicate, that EA is the most detrimental of the
fatty acids, while transVA may even be anti-inflammatory.
Besides inflammatory conditions, a significant factor in
development of CVD is the dysregulation of cholesterol
and lipoprotein levels. The liver is responsible for the se-
cretion and regulation of plasma proteins. In addition,
ingested fatty acids are metabolized by the liver and to-
gether with cholesterol redistributed to other organs
through lipoproteins. Thus, the hepatocyte responses to
individual TFAs are essential for understanding the
physiological effect of the intake of different TFAs.
Through proteomic, we have evaluated if human
hepatocellular cell line, HepG2-SF, responses to supple-
mented EA and transVA are comparable by reference to
their cis-isomers, oleic acid (OA) and cis-vaccenic acid
(cisVA). The cellular response to the TFAs EA and
transVA were compared and investigated by reference to
their naturally occurring cis-isomers OA and cisVA. Due
to cellular desaturation of transVA into conjugated lino-
leic acid (CLA) this fatty acid was also included. The
concentration of total free fatty acids in human blood
has been reported to be as high as 435 ± 11 μM and that
of a single free fatty acid, such as oleic acid, can be as
high as 158 ± 5 μM [26]. Previous studies of HepG2 cells
showed physiological relevant responses to free fatty
acids (ranging from 50 to 1000 μM) and further HepG2
cells expressed and secreted a broad range of known
plasma proteins important to lipid metabolism [27–33].
The lower concentration range of free fatty acids (50–
200 μM) only had a small effect on the cells [29, 31],
whereas the free fatty acids were cytotoxic at higher con-
centrations [28]. These previous studies using HepG2
cells mainly investigated OA, EA and palmitic acid in re-
lations to changes in cholesterol and lipoproteins levels.
We used 100 μM free fatty acid in complex with human
serum albumin, which mimics the natural transportation
of free fatty acids in the blood when fatty acids are not
transported as lipoproteins [32]. Further, we used the
commercial available HepG2-SF cell line adapted to
growth in serum free media (commercial available as
SynQ), which contains a minimal fatty acid formulation
(see Methods), this gives us crucial control of the presence
of fatty acids in the cell culture media supplemented with
the experimental fatty acids.
We used Stable Isotope Labeling by Amino acids in
Cell culture (SILAC) to investigate both cellular and se-
creted proteins from HepG2-SF cells in two separate
triplex setups where cells were supplemented with
transVA, cisVA or EA and transVA, OA or CLA. This
was chosen because of the limitation of multiplexing
more than three groups with SILAC. Further, Difference
in gel electrophoresis (DIGE) was used to investigate the
secretome from HepG2-SF cells supplemented with EA,
OA or cisVA. Special emphasis has been on analyzing
the secretome of EA and transVA supplemented cells, as
changes in particular plasma protein levels are essential
in the progression of CVD.
Results
Viability of HepG2-SF cells in fatty acid supplemented
medium
HepG2-SF cell viability in 100 μM fatty acid supple-
mented medium was analyzed using CyQuant NF prolif-
eration assay, as some C18 unsaturated fatty acids may
be cytotoxic for HepG2 cells at or above 100 μM [34].
During 7 days exposure, HepG2-SF cells were found
viable in the presence of 100 μM of all the fatty acids
tested (Fig. 1). Proliferation did not significantly differ
between cisVA and transVA and these did not differ
markedly from Control (no fatty acid supplementation)
either. Cells supplemented with CLA and OA did not
significantly differ from Control in cell numbers on day
7, however, CLA and OA supplemented cells showed
lower proliferation rates at the beginning of the experi-
mental period. Supplementation with EA causes a con-
siderable decrease in proliferation rate as compared to
the other experimental groups, which suggests that EA
directly or indirectly inhibit proliferation.
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Fatty acid esterification into TG of HepG2-SF cells
To test if the supplemented fatty acids were taken up by
the HepG2-SF and incorporated into TG, the fatty acid
composition of FAME derived from the HepG2-SF TG
fraction was analyzed by gas–liquid chromatography
(Fig. 2 and Additional file 1: Data S1). The result showed
that HepG2-SF cells take up the different supplemented
fatty acids and esterify them into their TG. Eukaryotes
are not able to make the fatty acid double bond of the
trans geometry, and so Control and cells supplemented
with cisVA do not contain TFA. Upon cisVA supplemen-
tation the content of this fatty acid in cell TG increase
from (8.3 ± 4.2) % to (24.1 ± 7.4) % (i.e. the supplemented
cisVA corresponds to 15.8 % ± 8.5 of total TG derived
FAME). Supplementing HepG2-SF cells for 7 days with
transVA, this fatty acid is present at 9.5 % ± 1.1 of the
TG (Fig. 2a). The relative amounts of the supplemented
geometrical isomers transVA and cisVA added to
HepG2-SF TG are thus comparable (9.5 % ± 1.1 and
15.8 % ± 8.5). This is in contrast to the relative amounts
of the positional trans-isomers EA and transVA, which
are very different, with EA present at approximately
three times the concentration of transVA (28.1 % ± 3.6
versus 9.5 % ± 1.1). In humans, transVA is desaturated
into CLA with a conversion rate estimated to be 19 %
[35]. We observed 2.47 % ± 0.16 CLA, when supple-
menting with transVA, corresponding to 21 % of the
combined transVA and CLA (Fig. 2b), thus reflecting the
estimated human conversion rate. Palmitic acid is the
measured non-supplemented fatty acid that differed the
most in amount between experimental groups, and is
lower when cells were supplemented with EA and OA
than compared to both supplementation with transVA
or cisVA (p < 0.05) and the largest difference is observed
between transVA and EA supplementation. In conclu-
sion, HepG2-SF cells take up and metabolize all the
supplemented fatty acids. However, after 7 days of sup-
plementation, the measured amounts of EA and transVA
isomers in TG differed between experimental groups,
indicating a differential lipid metabolic response to the
TFA isomers.
Identification and quantitation of proteins differentially
regulated by transVA, EA and cisVA using SILAC
SILAC was applied to investigate the cellular proteomic
response of the predominant rTFA and iTFA , transVA
and EA respectively, and compare their response to the
cisVA Both the secreted and the intracellular proteins
were investigated. A total of 3074 proteins were identi-
fied and of these 538 were quantifiable across all three
groups. In the trans-trans comparison EA/VA 25 pro-
teins were significantly regulated with a fold > 1.3. In the
trans-cis comparison transVA/cisVA 20 proteins were
significantly regulated with a fold > 1.3, and in EA/cisVA
24 proteins were significantly regulated with fold > 1.3.
A total of 47 differentially regulated proteins were found
(p < 0.01, fold > 1.3, Table 1 and Additional file 2: Data
S2). Functional clustering analysis showed that the most
significant functions represented by the regulated pro-
teins were lipid and cholesterol metabolic processes
including specifically cholesterol biosynthetic process.
Except for apoA1, the regulated proteins involved in
cholesterol synthesis are specifically up-regulated by EA
and not transVA, demonstrating that this response is
isomer specific. Eight of the 17 proteins categorized in
lipid metabolism process are up-regulated by EA when
compared to both transVA and cisVA and only 3 non-
lipid metabolism proteins (tricarboxylate transport pro-
tein–mitochondrial, membrane-associated progesterone
receptor component 1, and filamin-B) are regulated in
these comparisons.
Fig. 1 Viability and proliferation of HepG2-SF cells in fatty acid supplemented medium. Viability of HepG2-SF cells in medium supplemented with
100 μM OA, cisVA, CLA, transVA, EA, or no fatty acid (Control) was investigated using CyQuant proliferation assay. The measured fluorescence (y-axis)
corresponds to live cell numbers. During a seven days period cisVA, trans-VA, and Control do not markedly differ in proliferation rate, whereas EA,
though still viable, appear to be compromised on their proliferation. *significantly different from Control at p < 0.05
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Fig. 2 The fatty acid composition of HepG2-SF TG after fatty acid supplementation. HepG2-SF TG composition was analyzed by gas liquid
chromatography after 7 days incubation in fatty acid supplemented medium (100 μM). Panel a and b are high and low abundant fatty acids present
in the TG, respectively. Content of individual fatty acids (x-axis), analyzed as extracted FAME, are averaged over three biological replicas and displayed
as % of total TG derived FAME measured (y-axis). The supplemented TFAs esterify at different levels into HepG2-SF TG and EA is found at approximately
three times the level of transVA. The analysis shows that the supplemented fatty acids are taken up and metabolized by HepG2-SF cells. In addition, it
demonstrates that EA is accumulating in TG when compared to the other experimental groups. *significantly different from Control at p < 0.05. Fatty
acids significantly differing between experimental groups at p < 0.05 are marked with: a) different from OA, b) different from cisVA and c) different
from transVA
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Table 1 Differentially regulated proteins between trans-Vaccenic, cis-Vaccenic and Elaidic revealed by SILAC
Proteins are reported with Uniprot accession number, Name, Fold regulation in individual comparisons, the geometric standard deviation (Geo.SD.) and
selected GO-terms
a) black bold: significant regulatory data (p < 0.01) with fold > 1.3, black italic: significant regulatory data (p < 0.01) with fold < 1.3, grey italic: not significant
regulatory data (p > 0.01)
b) a: cholesterol biosynthetic process (GO:0006695), b: cholesterol metabolic process (GO:0008203), and c: lipid metabolic process (GO:0006629)
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Corticosteroid binding protein, classified in lipid metab-
olism, was down-regulated upon transVA-supplementa-
tion in both transVA/EA and transVA/cisVA. Heparin
cofactor 2 and fibrinogen alpha chain are non-lipid metab-
olism proteins regulated by transVA-supplementation.
They were both down-regulated. Three proteins were
down-regulated by both TFAs when compared to cisVA,
these were plasminogen activator inhibitor 1 (PAI1),
alpha-2-HS-glycoprotein (AHSG) and insulin-like growth
factor-binding protein 1 (IGFBP1). Transthyretin (TTR) is
up-regulated in both transVA/cisVA and EA/cisVA.
The SILAC analysis showed that the overlap of differen-
tially regulated proteins between the comparisons EA/
cisVA and transVA/cisVA is rather small, comprising 16 %
and 20 %, respectively, of regulated proteins at fold > 1.3,
p < 0.01. This suggests that cellular responses to the two
major dietary TFAs are rather different. However, a shared
TFA-induced response was observed for PAI1, AHSG,
IGFBP1, and TTR, as mentioned above.
Identification and quantitation of secreted proteins
differentially regulated by transVA, EA and cisVA using
DIGE
To further investigate the effects of TFA isomers on
plasma protein levels and to gain more information on
differentially regulated secreted proteins, the experimen-
tal medium from fatty acid supplementations of HepG2-
SF cells were analyzed by DIGE. Approximately 2000
spots were detected per gel and 1000 aligned across all
analytical gels. Using the criteria of 1.3 fold regulation at
p-value < 0.05 the numbers of differentially regulated
spots were 44 in EA/transVA and 5 in transVA/cisVA.
From the 44 differentially regulated spots in the trans-
trans comparison EA/transVA, 12 unique proteins (excl.
human serum albumin) were identified, and from the 5
differentially regulated spots in the trans-cis comparison
transVA/cisVA, 3 unique proteins were identified (Table 2
and Additional file 3: Data S3). EA, compared to transVA,
induced up-regulation of apoA1 and apoE, which are apo-
lipoproteins of HDL and VLDL respectively, and down-
regulation of AHSG, which inversely correlate with CVD
risk [36] and is suggested as a biomarker for TFA intake
[37]. ApoA4 was up-regulated in both EA/transVA and
transVA/cisVA. Four spots, upregulated by transVA when
compared to EA, were identified as complement C3 with
migration in the 2D gel estimated at a pI a little below 5
and a mass of approximately 40 kDa (Table 2, Additional
file 3: data S3 and Additional file 4: Figure S1). The pep-
tides, derived from the spots and identifying the proteins
as complement C3, all locate in the c-terminal part of C3
corresponding to the C3c alpha’ chain fragment 2. This
also fits the mass and pI observed, thus indicates increased
complement C3 activation by transVA. The DIGE results
thus support and supplement the SILAC results, as will be
discussed, which further underline the indication that the
major iTFA (EA) and the major rTFA (transVA) promote
relatively different hepatocellular responses.
Identification and quantitation of proteins differentially
regulated by transVA, OA and CLA using SILAC
OA is the most abundant of naturally occurring C18:1 cis
fatty acids in food stuff, and it was included in a separate
SILAC analysis comparing OA-supplemented cells to
transVA, to test if the transVA induced response, observed
in the transVA-cisVA-EA comparison described above,
could also be confirmed with reference to OA. CLA was
included in this second SILAC setup, as mammalian cells
are able to further desaturate transVA to yield CLA. The
cellular response to 100 μM CLA was investigated to as-
sess if the transVA to CLA conversion contributes to the
observed transVA response.
A total of 3191 proteins were identified in this second
SILAC triplex setup and of these 15 were differentially
regulated in the transVA/OA comparison within the fold
1.3 criteria set, p < 0.01. For CLA/transVA and CLA/OA
the numbers were 26 and 39, respectively (Additional file
5: Data S4). Five of the 15 proteins significantly regulated
in transVA/OA were also regulated in the first SILAC
transVA-cisVA-EA triplex. The down-regulation of AHSG,
fibrinogen alpha chain and corticosteroid binding globulin
was confirmed in transVA/OA together with down-
regulation of glypican 3 and stanniocalcin 2.
If the cellular response to transVA was in part medi-
ated by its conversion to CLA, supplementation with
100 μM CLA would be expected to enhance the re-
sponse observed during supplementation with transVA.
Ten of the 26 proteins significantly regulated in the CLA/
transVA comparison were also regulated in the first
SILAC transVA-cisVA-EA triplex. Eight of these were in
CLA/VA regulated in the opposite direction as in the
transVA/cisVA comparison. This demonstrates that the
transVA induced response is not significantly contributed
by the presence of CLA, and furthermore the data sug-
gests that the cis-desaturation on the Δ9 position in CLA
may neutralize some of the effects of the Δ11 trans-double
bond.
Discussion
Investigations of adverse health effects related to TFA
intake have not focused on the contribution of the indi-
vidual positional TFA isomers. We have in earlier studies
investigated the differential response of human hepato-
cytes, HepG2-SF, to the two geometric Δ9C18:1 isomers
OA (cisΔ9C18:1) and EA (transΔ9C18:1). The studies re-
vealed substantial differences in abundance of proteins
involved in cholesterol synthesis and lipid metabolism in
general and furthermore indicated remodeling of the
phospholipids caused by the EA supplementation of the
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cells [37, 38]. In the present study, we investigate if the
hepatocellular responses to the two most abundant pos-
itional C18:1 TFA isomers in the human diet, EA and
transVA, are comparable. The cisVA was included to test
if also the Δ11C18:1 geometrical isomers showed the
same affect on HepG2-SF cells, as previously shown for
the Δ9C18:1 geometrical isomers.
Supplemented trans fatty acids esterify at different
amounts into the TG of liver cells
To our knowledge, TFA induced hepatic responses have
not earlier been investigated in human cell cultures,
although a study using rat hepatocytes showed that
short-term (2 h) exposure to EA or transVA causes equal
incorporation of the TFAs into TG [39]. Contrary to the
results in rats, we showed, by the analyses of FAME
derived from HepG2-SF TG, that after 7 days supple-
mentation with EA or transVA that the TG fraction
contained more than double the amount of EA to that
of transVA. Upon supplementation, transVA and cisVA
esterified to similar extend into the TG fraction. TG acts
as a cellular storage site for fatty acids, which can be
used for energy production through β-oxidation in mito-
chondria and peroxisomes. In rat the β-oxidation rate of
EA has been shown to be 30 % lower than for both
transVA and cisVA [40] because a β-oxidation intermedi-
ate of EA slows β-oxidation progress [41]. If this occurs
in human cells, EA may thus be accumulating in TG as
β-oxidation slows down and this may be the reason for
our observation of different relative amounts of TFAs in
HepG2-SF TG. However, the total amounts of TG per
cell in each experimental group were not determined in
the present study. Consequently, it cannot be concluded
if EA-containing TGs are added to the TG pool or if EA
substitutes for other fatty acids, for example palmitic
acid, keeping total TG at a constant amount.
Table 2 Differentially regulated secreted proteins revealed by DIGE and identified by mass spectrometry
EA/transVA transVA/cisVA
Protein name Uniprot name spot no Av. Ratio p-value Av. Ratio p-value
14-3-3 protein zeta/delta 1433Z/P63104 2180 −1.43 3.0E-02
Aldose 1-epimerase GALM/Q96C23 1832 2 2.5E-03
Alpha-1-antitrypsin A1AT/P01009 1330 1.79 3.6E-04
Alpha-1-antitrypsin 1342 1.96 3.9E-03
Alpha-2-HS-glycoprotein FETUA/P02765 1400 −1.51 3.4E-02
Apolipoprotein A1 APOA1/P02647 2333 1.57 2.0E-04
Apolipoprotein A4 APOA4/P06727 1737 1.57 7.3E-03 1.39 4.8E-02
Apolipoprotein A4 1741 1.7 1.7E-04 1.4 2.8E-03
Apolipoprotein A4 1743 1.43 2.3E-02
Apolipoprotein E APOE/P02649 2030 1.39 5.9E-03
Carboxypeptidase E CBPE/P16870 1417 −1.78 1.3E-03
Chloride intracellular channel protein1 CLIC1/O00299 2106 1.75 1.9E-03
Complement C3 CO3/P01024 1675 −1.41 3.1E-02
Complement C3 1706 −1.51 4.6E-03
Complement C3 1708 −1.51 4.6E-03
Complement C3 1710 −1.51 8.8E-04
Complement factor B CFAB/P00751 726 −1.32 2.5E-03
Endoplasmin ENPL/P14625 737 −1.51 4.8E-02
Proteasome subunit alpha type-5 PSA5/P28066 2203 −1.37 4.7E-02
Protein AMBP AMBP/P02760 2042 1.62 2.2E-03
Serotransferrin TRFE/P02787 1005 1.56 8.0E-04
Serotransferrin 1007 2.02 2.7E-04
Serotransferrin 1033 1.65 1.5E-04
Serotransferrin 1765 1.43 1.1E-02
The secretome of hepatocytes supplemented with transVA, EA, or cisVA were analyzed by DIGE and subsequently the regulated proteins were identified by LC-
MS/MS analyses. In the table proteins are reported with protein name, Uniprot name/accession number, 2D gel spot number (spot no), Average ratio (Av.ratio),
and p-value for individual comparisons
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EA and transVA affect lipid metabolism-related proteins
differently
The cellular proteomic responses to EA, transVA and
cisVA were analyzed using SILAC and DIGE. The SILAC
analysis identified 47 differentially regulated proteins in
EA/transVA, transVA/cisVA and/or EA/cisVA (Table 1)
and functional cluster analysis showed that the main per-
turbed cellular functions are lipid and cholesterol metab-
olism. In a previous study, comparing the HepG2-SF
responses to EA and OA, we found that the major part of
proteins associated with cholesterol synthesis were up-
regulated in the TFA treated cells [38]. Moreover, in rat
hepatocytes EA supplementation caused an increased
cholesterol efflux as compared to both transVA and cisVA
[39]. In the present study, we find several of the proteins
involved in lipid metabolism, and especially cholesterol
synthesis, to be up-regulated by EA, when compared to
both transVA and cisVA. It supports the findings in rats
and suggests that the increased cholesterol efflux is in part
a result of increased synthesis. Also, Proprotein convertase
subtilisin/kexin type 9 (PCSK9) was up-regulated in both
EA/transVA and EA/cisVA but unchanged in transVA/
cisVA. This protein can cause degradation of LDL-
receptor [42] and thereby possibly decrease the LDL-
cholesterol uptake by the cell contributing to extracellular
cholesterol accumulation. DIGE was performed on the se-
creted proteins from HepG2-SF cells, because it has been
suggested that TFA may influence CVD risk by altering
secretion of plasma proteins from the liver. Our DIGE
data shows that apoA1, which is the major apolipoprotein
of HDL, is up-regulated by EA when compared to
transVA and unchanged in transVA/cisVA (Table 2). In
SILAC the regulatory data for apoA1 is 1.2 fold for EA/
VA and −1.3 fold for transVA/cisVA. Cholesteryl ester
transfer protein is responsible for cholesteryl ester transfer
from HDL to LDL and its activity is increased by TFA
[43]. If ApoA1 is up-regulated by EA, this may cause an
increased extracellular capacity for cholesterol, and with
increased CETP activity this may aid cholesterol accumu-
lation in LDL.
Trans fatty acid specific responses
The SILAC analysis revealed four proteins that were sig-
nificantly regulated in the same direction, but not neces-
sarily to the same extent, by both TFAs when compared to
cisVA. These included TTR, which is up-regulated, and
PAI1, IGFBP1 and AHSG, which are down-regulated. We
have in a previous biomarker study compared EA with
OA and among other candidates found TTR, PAI1,
IGFBP1 and AHSG as potential biomarkers for TFA-
intake [37]. The present study supports that the regulation
of these proteins are TFA specific. Decreased level of me-
talloproteinase inhibitor 1 (TIMP1) was also suggested as
a potential biomarker for EA intake [37], and this protein
was down-regulated in EA/cisVA (−1.42) and just below
the fold cut-off in transVA/cisVA (−1.27), also indicating
this to be a TFA-specific response.
In the previous biomarker study PCSK9, ApoA4, tissue
factor pathway inhibitor (TFPI), AHSG, and serotransfer-
rin were also shown to be potential biomarkers for EA
supplementation, when compared to OA [37]. PCSK9,
ApoA4 and serotransferrin were up-regulated, TFPI and
AHSG down-regulated. In the present investigations,
SILAC analysis confirmed that PCSK9 and ApoA4 were
up-regulated and potential EA biomarkers. TFPI was
down-regulated by transVA when compared to cis-VA
(−1.33), and the fold down-regulation in EA/cisVA was
1.15. Serotransferrin was up-regulated in EA/cisVA (1.31),
but lacked significance in regulation in the other compari-
sons. In the DIGE characterization of the proteins se-
creted by HepG2-SF cells, ApoA4 and serotransferrin
were up-regulated (on average 1.57 and 1.67, respectively)
and AHSG down-regulated (−1.51) in the EA/VA com-
parison (Table 2), confirming the observed changes in the
EA/OA comparison [37] underlining that these are poten-
tial biomarkers for EA intake. However, ApoA4 was also
up-regulated in the DIGE transVA/cisVA comparison
(1.4), which shows that this response is not EA-specific
though more pronounced by EA than by transVA supple-
mentation. Noteworthy, all the regulated and discussed
proteins (PCSK9, AHSG, ApoA4, TIMP1, TFPI, PAI1 and
IGFBP1) have previously been mentioned in the context
of CVD risk [36, 37, 44–47].
However, 18 of the 26 proteins differentially regulated
in CLA/transVA categorize with the GO-term: Response
to stress, all up-regulated by CLA, and seven of these
are part of the acute inflammatory response. This may
indicate that the high concentration of CLA is stressful
or even toxic for HepG2-SF cells, though not decreasing
viability after a seven days period. A blood concentration
of 100 μM CLA is not easily reached through diet, and
though interesting it is beyond the scope of this paper to
further discuss the cellular response to CLA.
The complement system is affected by TFA
Artherosclerosis is considered an inflammatory condition
[48]. It has been suggested that dietary TFA induces
vascular inflammation and effects on several markers of
endothelial cell dysfunction and inflammatory responses
have been documented [24, 49, 50]. Though a TFA,
transVA did not induce this effect in endothelial cells and
may even protect against vascular inflammation measured
as decreased T-helper cell cytokine production [24, 25].
Part of the vascular inflammatory response is the activa-
tion of the complement system, and a key protein is
complement factor C3 (CO3). Blood CO3 is a predictor of
myocardial infarction [51] and correlates positively with
obesity and coronary artery disease [52]. In the DIGE
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study we identify CO3 in 4 spots, up-regulated by transVA
when compared to EA and unchanged when compared to
cisVA (Table 2, Additional file 3: Data S3 and Additional
file 4: Figure S1). These spots correspond to the most C-
terminal part of CO3, the C3c alpha chain fragment 2.
By SILAC it is observed that the overall CO3 level is
significantly increased by EA compared to transVA
(1.27 fold), and up-regulation in cisVA/VA is also indi-
cated (Additional file 2: Data S2). The regulatory data
for CO3 suggests that supplementation with transVA gives
the lowest overall level of CO3, but the highest level of
CO3 activation relative to total amount. Complement fac-
tor B is also an important protein in the complement sys-
tem, which upon binding to CO3 b fragment interacts
with and activates complement factor D, which in turn
cleaves factor B [53]. The cleaved form of factor B forms a
complex with the CO3 b fragment in the formation of C3
convertase, which further accelerate the cleavage of CO3.
Complement factor B was significantly up-regulated 1.2
fold in SILAC in both EA/VA and cisVA/transVA i.e.
down-regulated by transVA (Additional file 2: Data S2). In
DIGE judging by mass, pI, spot pattern, and identification
by MS/MS, the full-length complement factor B was ob-
served as a train of spots, with one spot up-regulated 1.42
fold and another down-regulated 1.32 fold in EA/VA. This
observation in DIGE suggests a change in the glycosyla-
tion pattern, with an EA induced deglycosylation of factor
B. Deglycosylation at Asn260 of factor B causes increased
affinity for the CO3 b fragment [54] and deglycosylation
at Asn353 is suggested to increase cleavage by factor D
and thus deglycosylation at both sites can increase forma-
tion of the C3 convertase [55]. Whether the observed
change in spot pattern on our 2D gels is due to deglycosyl-
ation at either of the mentioned sites, with implication for
complement activation due to EA, requires further
investigations.
Some proteins categorized in the acute inflammatory/
acute phase response are also regulated by the TFAs inves-
tigated, though not clearly confirming or rejecting an
acute phase response. These include the positive acute
phase proteins: fibrinogen alpha chain (SILAC: EA/VA
1.55 fold, transVA/cisVA −1.73 fold), PAI1 (SILAC: EA/
cisVA −1.39, transVA/cisVA −1.35), serum amyloid A-4
(SILAC: EA/transVA 1.33, transVA/cisVA −1.27) and fer-
ritin light chain (SILAC: EA/transVA −1.57, transVA/
cisVA 2.06), and the negative acute phase proteins: AHSG
(SILAC: EA/cisVA −1.32, transVA/cisVA −1.38; DIGE EA/
VA −1.51), serotransferrin (SILAC: EA/cisVA 1.31; DIGE
EA/transVA 1.67) and TTR (SILAC: EA/cisVA 1.97,
transVA/cisVA 3.47).
Regulators of blood coagulation are affected by TFA
By SILAC fibrinogen alpha chain was the only protein to
be significantly regulated specifically by transVA when
compared to both EA and cisVA (−1.55 and −1.73
fold regulation, respectively). Though not significant
at p < 0.01 both fibrinogen beta and gamma chain also
showed approximately 1.6 fold down-regulation by
transVA supplementation (Additional file 2: Data S2).
PAI1 was decreased by both EA and transVA. Increased
plasma fibrinogen and PAI1 levels correlates with in-
creased thrombosis risk [44, 56], and thus transVA may
have a potential beneficial influence on the level of these
proteins in regards of CVD risk. However, the observed
decrease in level of fibrinogen could also indicate a
transVA-induced shift towards coagulation of the equilib-
rium between coagulation and fibrinolysis, resulting in
consumption of fibrinogen. The possibility of increased
coagulation is supported by the observation that both
TFPI and heparin cofactor 2 are also decreased by
transVA-supplementation. TFPI is a major inhibitor of the
extrinsic coagulation pathway through its interaction with
Factor Xa and tissue factor-factor VIIa complex [57, 58],
and heparin cofactor 2 inhibits thrombin action [59], thus
low level of both may promote thrombophilia. Whether
transVA promotes or protects against thrombophilia is
thus difficult to conclude from the present experiments,
however it clearly affects levels of regulators of blood
coagulation.
Conclusion
It has previously been established that iTFAs correlate
with CVD risk [3]. However, a diet very high in rTFA also
negatively affects CVD risk factors [20]. It has therefore
previously been discussed if transVA and EA in food have
different effects on human health, or whether it is merely
a matter of the total dietary TFA amount consumed [60].
Our study shows that partially differential hepatocellular
responses to the two C18:1 TFA isomers transVA and EA
occurs. EA specifically induces an increase in proteins
involved in cholesterol synthesis and cholesterol transport,
a response not shared with transVA. The results of this
investigation suggest that EA has an adverse effect on
cholesterol metabolism that could be unique to the main
TFA isomers found in foodstuff and explain its stronger
correlation with CVD risk than for transVA, but this
requires more investigations in animal models and ultim-
ately in clinical intervention studies.
Methods
Materials
Cis-vaccenic acid (> 97 % purity) and Conjugated linoleic
acid (> 96 % purity) were purchased from Cayman Chemi-
cals. 13C6Arginine and
13C6
15N4Arginine (both 99 % purity)
were from Cambridge isotope laboratories (Andover, MA,
USA). Elaidic acid, Oleic acid, trans-vaccenic acid , L-
Lysine and Arginine (all 99 % purity), Anhydrous dimethyl
formamid (99.5 % purity), iodoacetamide, tetra-methyl-
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ethylene-diamine, L-Glutamine, Human serum albumin
and RPMI-1640 without Arginine, Lysine and Leucine
were purchased from Sigma. Regular SynQ serum substi-
tute and SynQ without Arginine and Lysine was from Cell
Culture Service, Hamburg Germany. All reagents for
DIGE were PlusOne quality from GE Healthcare. Also
CyDye DIGE fluors, IPG running buffers and PD10 col-
umns were purchased from GE Healthcare. Penicillin,
Streptomycin, regular RPMI-1640 and CyQuant NF prolif-
eration assay kit were from Invitrogen.
Cell culture
HepG2-SF cells (HepG2 cells optimized for serum free
growth, Cell Culture Service, Hamburg, Germany) were
propagated in 75 cm2 Nunc™ culture flasks in serum free
medium composed of RPMI-1640, 10 % SynQ Serum sub-
stitute (Contains: Oleic acid, 3.5 μM; Linoleic acid,
500 ng/mL; Thioic acid, 250 ng/mL), 4 mM L-glutamine,
20 U/mL penicillin and 20 μg/mL streptomycin, which
was changed every third day. Cells were maintained at
37 °C in a 5 % CO2 humidified incubator and subcultured
every two weeks. For preparation of fatty acid supple-
mented medium, fatty acid in a 2:1 molar complex with
human serum albumin [61] was adjusted to a final con-
centration of 100 μM in serum free medium.
Assessment of HepG2-SF growth in fatty acid
supplemented medium by CyQuant proliferation assay
In a 96 well (low fluorescence) microtiter-plate 5,500 cells
were seeded per well and allowed to attach for 24 h before
300 μl 100 μM fatty acid supplemented regular medium
was added (4 replicas for each experimental group). On
day 0, 3, 5 and 7 after addition of supplemented media
proliferation was assessed by adding 100 μl CyQuant dye
solution per well, and after 30 min incubation at 37 °C
fluorescence was measured using a FLUOstar Omega
(BMG Labtech) until a plateau was reached (excitation
480 nm, 520 nm emission, 3 h). For comparison of experi-
mental groups with Control equality of variance were
tested (F-test) and appropriate two-tailed t-tests were
performed.
Measurement of fatty acids esterified into triacylglycerols
(TG) by gas–liquid chromatography
For each experimental group 3 replicas of three million
cells each, incubated 7 days in fatty acid supplemented
serum free medium as described above, were washed 2
times in sucrose buffer (250 mM sucrose, 50 mM KCl,
2 mM MgCl2, 20 mM Tris–HCl, pH 7.6) and scraped off
the petridish in 1 ml sucrose buffer. Cells were centrifuged
for 3 min at 180 g and the supernatant was discarded. Pel-
lets were resuspended in methanol, vortexed and trans-
ferred to glass tubes with Teflon lined caps. Lipids were
extracted with methyl-tert-butyl-ether according to [62]
and subjected to thin layer chromatography on 20 × 20
cm silica gel 60 plates with glass backing (Merck) using a
two-buffer system (buffer 1, 30 min: chloroform:methano-
l:acetic acid:water-50:30:8:3, buffer 2, 45 min: heptane:-
diethyl ether:acetic acid – 70:30:2). Plates were dried after
the development and lipids were visualized by placing the
plates in an iodine chamber, the TG bands were marked
and scraped off the plate when iodine was evaporated. TG
were extracted from silica with chloroform:methanol (2:1)
and dried. Fatty acid methyl esters (FAME) were gener-
ated from the TG using BF3. First samples were mixed
with 1 ml methanolic NaOH (0.5 M) and heated for 5 min
at 80 °C. After cooling to room temperature 1 ml of BF3-
methanol (13–15 %) was added and again samples were
heated at 80 °C for 2 min and cooled rapidly to room
temperature. To improve FAME extraction to the or-
ganic phase, 0.2 ml of a salt solution containing NaCl2
(370 mg/ml) and K2CO4 (1.5 mg/ml) in water was added
followed by 1 ml of heptane. After 5 min centrifugation at
4000 rpm the upper organic phase was isolated and dried
over anhydrous Na2SO4 before application to gas–liquid
chromatography. The FAME were analyzed on a Thermo
Trace GC Ultra (Thermo Scientific, USA) equipped with
auto-sampler, flame ionization detector and a Supelco
SLB-IL100 column (60 m x 0.25 mm x 0.2 μm film thick-
ness, Sigma-Aldrich). Helium was used as a carrier gas
with a flow rate of 1 ml/min. An isothermal program at
180 °C for 25 min was applied. The injector and detector
temperatures were set at 200 °C and 220 °C, respectively.
Five μl samples with a split flow of 10:1 were injected.
Using Xcalibur software fatty acids were identified by
comparing their retention times to standard mixtures and
those eluting between 11.5 min and 23.5 min are
expressed as mol % based on an internal standard (methyl
heptadecanoate).
Incubation of HepG2-SF cells in fatty acid supplemented
media for Stable Isotope Labeling by Amino acids in Cell
culture (SILAC)
Serum free medium was prepared from RPMI-1640 with-
out Arginine, Lysine and Leucine and SynQ without
Arginine and Lysine. The medium was then supplemented
with Leucine and Lysine to a final concentration of
0.38 mM and 1.02 mM, respectively. From this medium
three different SILAC growth media were prepared con-
taining 1.15 mM Arginine, 13C6Arginine or
13C6
15N4Argi-
nine. To facilitate full incorporation of 13C6Arginine and
13C6
15N4Arginine the cells were cultivated as described
above for 5 population doublings with medium change
every third day. The level of incorporation was tested by
MALDI-MS prior to incubations with fatty acids in SILAC
media. For preparation of fatty acid supplemented
medium fatty acid in a 2:1 complex with human serum
albumin [61] was adjusted to a final concentration of
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100 μM in SILAC serum free medium. Two SILAC triplex
setups were made one using transVA (Arginine), EA
(13C6Arginine) and cisVA (
13C6
15N4Arginine), the other
using transVA (Arginine), OA (13C6Arginine) and CLA
(13C6
15N4Arginine).
For each experimental group 75 cm2 culture flasks con-
taining 90 % confluent cells were trypsinized and seeded
into four 6 cm petri dishes (= four replicas/experimental
group). Cells were allowed to attach for 24 h before 3 mL
fatty acid supplemented medium was added. The medium
was changed on day two, four and six. On day 7 medium
was aspirated and filtered (Sarstedt syringe filters,
0.22 μm) and kept on ice until further processing as de-
scribed below. Cells were trypsinized, washed three times
in cold PBS and lysed in lysis buffer (1 % NP-40, 150 mM
NaCl, 50 mM Tris, 0.1 % SDS, 1 mM PMSF, 25 μM E64,
2 mM 1.10 Phenanthroline, pH 7,4) by sonication on ice.
Lysate was centrifuged (16000 g, 4 °C) and supernatant
collected and kept on ice.
SILAC sample preparation
Cell medium was depleted for albumin by affinity chro-
matography on a column with a recombinant albumin
binding domain from Streptococcal protein G [63]. The
flow through was collected and the column regenerated
using 20 mM Na-citrate, 150 mM NaCl, pH 2.5 before
application of next sample. Between experimental
groups the column was cleaned using 30 % isopropanol,
2 M NaCl. Protein concentration in depleted samples
were determined using Bradford assay kit [64]. The 4
biological replicas in each group were pooled based on
protein concentration and then the pools from different
fatty acid incubations were mixed in a 1:1:1 ratio. The
protein concentration in cell lysates were determined by
2D-Quant kit (GE Healthcare) and mixed as described
for cell medium samples. Proteins from medium and ly-
sates were separated in individual lanes by SDS-PAGE
[65] and each lane was cut into bands. Proteins in the
bands were in-gel digested using trypsin [66] and subse-
quently the resulting peptides were desalted on C18
stage tips (Proxeon).
LC-MS/MS of SILAC samples
The peptides were separated on an Easy-nLC II HPLC
system (Thermo Scientific) equipped with a trap column
(ReproSil-Pur C18-AQ (5 μm, 2 cm x 100 μm I.D.,
Thermo Scientific) and an analytical column (ReproSil-
Pur C18-AQ column, 3 μm, 10 cm x 75 μm I.D., Thermo
Scientific) in-line to a NanoSpray III source (AB Sciex)
connected to a TripleTOF 5600 mass spectrometer (AB
Sciex) operated under Analyst TF 1.5.1 control. Peptides
were eluted at a constant flow of 250 nl/min with a
50 min gradient from 5 to 35 % solvent B (90 % ACN,
0.1 % formic acid) followed by re-equilibration for 10 min
back to the starting conditions. Information dependent ac-
quisition was employed acquiring up to 25 MS/MS spec-
tra per cycle using 1.6 s cycle time with an exclusion
window of 6 s.
SILAC data analysis
All raw MS files were processed using Mascot Distiller
2.5.0 (Matrix Science). The MS data obtained by the ana-
lysis of gel lanes were merged into a multi-file-project
using the default settings from the ABSciex_5600.opt file
except that the MS/MS Peak Picking “Same as MS Peak
Picking” was deselected and “Fit method” was set to “Sin-
gle Peak”. After peak picking all scans, the data were
searched against Swiss-Prot Homo Sapiens database (v.
2013_11/12) using Mascot v. 2.3.02 (Matrix Science) [67].
The Search parameters allowed one missed trypsin cleav-
age site, propionamide as a fixed modification, and oxida-
tion of methionine as a variable modification. The mass
accuracy of the precursor and product ions were set to
10 ppm and 0.2 Da, respectively, the instrument setting
was specified as ESI-QUAD-TOF, and a significance
threshold of 0.01 was used. The default SILAC R + 6 R +
10 [MD] quantitation protocol was selected using a sig-
nificance threshold at 0.01, matched rho was 0.7, XIC
threshold was 0.1, isolated precursor threshold was set at
0.5 and normalization set to median. Mascot Distiller re-
sults were exported to xml files, imported into MS Data
Miner v.1.2.0 (http://sourceforge.net/p/msdataminer [68])
and exported into Excel reports. Keratin was excluded as a
general contaminant and a fold regulation threshold of 1.3
was selected for significant differentially regulated pro-
teins. Spectra for differentially regulated proteins were
manually inspected and proteins were excluded if not at
least two unique peptides showed peaks for both light,
medium and heavy label significantly above background
(ion counts > 50). The data are available via ProteomeX-
change with identifier PXD000760 (http://proteomecen-
tral.proteomexchange.org). Clustering analysis was done
using the Functional Annotation tools of DAVID Bioinfor-
matics Resources 6.7 [69, 70].
Incubation of HepG2-SF cells in fatty acid supplemented
media for DIGE
Four 75 cm2 culture flasks containing 90 % confluent cells
were trypsinized and seeded into 16 new flasks (4 replicas/
group), and allowed to attach for two days before addition
of fatty acid supplemented medium (10 ml/flask). Medium
was changed on day 3 and 6. On day 6 only 5 ml fatty acid
supplemented medium was added. The 5 ml conditioned
medium was collected on day 7, filtered, and stored on
ice. Samples for DIGE was depleted for albumin as de-
scribed for SILAC above and desalted using a PD10 col-
umn into 2.5 mM Tris, pH 7.4. Aliquots of 50 μg protein
were dried in a SpeedVac and stored at −20 °C until use.
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DIGE analysis of proteins secreted by HepG2-SF cells
A total of 50 μg of protein was labeled using GE Health-
care CyDye DIGE Fluors (minimal dyes) according to the
manufacturers instructions (GE Healthcare). The samples
were labeled using 400 pmol Cy3 or Cy5 and as an in-
ternal standard, a pool of 25 μg of each sample to be ana-
lyzed was labeled by 400 pmol Cy2 per 50 μg protein.
Labeling was conducted in 7 M Urea, 2 M Thiourea,
4 % w/v CHAPS, 10 mM Tris, pH 8.5. After 30 min incu-
bation the labeling reaction was quenched by adding 1 μl
10 mM lysine. Four experimental groups with 4 replicas
were analyzed (two replicas in each group labeled with
Cy3 and two with Cy5) resulting in a total of 8 analytical
DIGE gels. The combination of samples differed in all gels
and no gels contained two replicas from the same experi-
mental group. Two samples labeled with Cy3 and Cy5 re-
spectively were mixed with 50 μg Cy2-labeled internal
standard and volume adjusted to 130 μl in rehydration
solution (7 M Urea, 2 M Thiourea, 4 % w/v CHAPS,
0.5 % v/v pH4-7 IPG carrier ampholytes, 40 mM DTT,
10 mM Tris, pH 8.5). The mixed samples were incubated
in the dark, rotating at room temperature for 20 min and
centrifuged 30 min at 16000 g. Supernatants were sub-
jected to isoelectric focusing by cup-loading on 24 cm
pH 4–7 Immobiline Drystrips (GE Healthcare) rehydrated
overnight in rehydration solution. Isoelectric focusing
was performed in an Ettan IPGphor II (GE Healthcare) at
25 °C with maximum 50 μAmp/strip using the following
program: step 1 h at 150 V, gradient 1 h to 500 V, step 2 h
at 500 V, gradient 7 h to 1000 V, gradient 4 h to 8000 V,
step 5 h 8000 V.
After focusing, proteins in IPG-strips were reduced with
DTT (10 mg/ml in equilibration buffer composed of
50 mM Tris, 6 M Urea, 30 % glycerol, 2 % SDS, pH 8.8)
for 15 min followed by alkylation 15 min with iodoaceta-
mide (25 mg/ml in equilibration buffer). The strips were
equilibrated in upper reservoir Laemmli buffer (50 mM
Tris, 384 mM Glycine, 0.2 % w/v SDS) and placed on top
of an acrylamide/bis (10 % T, 0.87 % C) Tris–HCl, pH 8.8,
gel in low fluorescent glass plates. Second dimension elec-
trophoresis was conducted in the Ettan Dalt six gel system
(GE Healthcare) program as follows: 2 h at 0.3 W/gel,
10 h at 1 W/gel, 4 h at 2 W/gel.
DIGE-gels were scanned on Typhoon 8600 scanner at a
pixel resolution of 100 μm, the photomultiplier tubes at
600 V and laser and emission filters set at standard DIGE
scanning. DeCyder software v. 6.0 (GE Healthcare) was
used for image analysis. Spots more than 1.3 fold regu-
lated with a p-value < 0.05 were selected for spot-picking.
A preparative gel with a protein load of 400 μg pro-
tein was prepared using the same conditions as de-
scribed above. The gel was stained using coomassie
blue G250 (Merck) and scanned (red laser, 633 nm).
In DeCyder the gel was aligned with the DIGE gels
and regulated spots were picked using an Ettan spot-
picker (GE Healthcare).
Identification of proteins of interest using LC MS/MS
Picked gel plugs were dehydrated and destained using
acetonitrile and NH4HCO3 and the gel-plugs were dried
before reswelling in 50 mM NH4HCO3 with 100 ng
trypsin (Promega) pr plug and left over night at 37 °C
for in-gel digestion [66]. At the end of digestion, formic
acid was added. Peptides were purified on C18 reverse
phase material using Stage-tips and eluted with 2 μl
70 % acetonitrile into 18 μl 0.1 % formic acid. The sam-
ples were subjected to LC MS/MS using an Easy nLC
(Proxeon) (50 min gradient of 5–40 % acetonitrile in
0.1 % formic acid) coupled in-line with a Q-TOF Ultima
API mass-spectrometer (Micromass/Waters). Data were
processed using MassLynx 4.0 software (Waters). MS/
MS data are searched against SwissProt (v. 2014_02)
limited to human taxonomy using Mascot v. 2.3.02
(Matrix Sciences). Trypsin was selected and a maximum
of one missed cleavage was allowed. The following vari-
able modifications were accepted: Carbamidomethyl,
propionamide, and oxidation on methionine. Peptide tol-
erance was set at 1.2 Da and MS/MS tolerance at
0.6 Da. Instrument setting was specified as ESI-QUAD-
TOF. Protein identifications were based on significant
MOWSE-score, peptide scores > 30, low e-values, and
visual inspection of MS/MS spectra. Spots were ex-
cluded from further analysis if identified as albumin, due
to the use of albumin as delivery vehicle for fatty acids.
Additional files
Additional file 1: Data S1. GLC. Results from the gas–liquid
chromatography analysis. On the left are in bold averages of mol% for
three biological replicates and on the right their respective standard
deviations. Raw data is provided for each replicate in separate sheets.
(XLSX 48 kb)
Additional file 2: Data S2. SILAC transVA-EA- cisVA. Data from the
SILAC investigation of the cellular response to transVA, EA and cisVA.
(XLSX 867 kb)
Additional file 3: Data S3. DIGE identifications. Protein identifications
by LC-MS/MS from DIGE analysis of the secretomes from cells incubated
with transVA, EA and cisVA. Spots with significantly different intensities
between samples in the DIGE analysis were excised, and the proteins
were identified by LC-MS/MS and Mascot searches. Proteins identified
by≥ 2 unique peptides with ion scores ≥ 30 are highlighted. (XLSX 23 kb)
Additional file 4: Figure S1. DIGE 2D-gel with indications of the
significant differentially regulated spots in EA/transVA (panel A) and transVA/
cisVA (panel B). The numbers correspond to Table 2 and supplemental data
S3. (DOCX 1198 kb)
Additional file 5: Data S4. SILAC transVA-OA-CLA. Data from the SILAC
investigation of the cellular response to transVA, OA and CLA. In sheet 1,
“full data”, unfiltered data from this second SILAC triplex is displayed. In
sheet 2, “signif. 1.3 fold”, proteins significantly regulated≥ 1.3 fold in≥ one
comparison are displayed. Proteins are reported with Uniprot accession
number, Name, Fold regulation in individual comparisons, the geometric
standard deviation (Geo.SD.), and selected GO-terms: GO:0006950 response
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to stress (x) and GO:0002526 acute inflammatory response (y). Black bold:
significant regulatory data (p < 0.01) with fold > 1.3, black italic: significant
regulatory data (p < 0.01) with fold < 1.3, grey italic: not significant regulatory
data (p > 0.01). (XLSX 925 kb)
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